BIORESTORATIVE THERAPIES INC (BRTX) Forecast, Price Target & Analyst Ratings
NASDAQ:BRTX • US0906556065
0.2129 USD
+0 (+1.14%)
At close: Mar 6, 2026
0.2143 USD
+0 (+0.66%)
After Hours: 3/6/2026, 8:03:35 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIORESTORATIVE THERAPIES INC (BRTX).
Forecast Snapshot
Consensus Price Target
$9.69
+ 4,451.43% Upside
Next Earnings Forecast
Release DateMar 26, 2026
PeriodQ4 / 2025
EPS Estimate-$0.38
Revenue Estimate153K
ChartMill Buy Consensus
82.50%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$9.69
Upside
+ 4,451.43%
From current price of $0.21 to mean target of $9.69, Based on 8 analyst forecasts
Low
$1.01
Median
$9.69
High
$18.90
Price Target Revisions
1 Month
-26.92%
3 Months
-26.92%
Price Target Summary
8 analysts have analysed BRTX and the average price target is 9.69 USD. This implies a price increase of 4451.43% is expected in the next year compared to the current price of 0.2129.
The average price target has been revised downward by 26.92% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
BRTX was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about BRTX.
In the previous month the buy percentage consensus was at a similar level.
BRTX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-08-14 | Roth MKM | Maintains | Buy -> Buy |
| 2024-06-12 | Roth MKM | Maintains | Buy -> Buy |
| 2023-08-14 | Roth MKM | Reiterate | Buy -> Buy |
| 2022-12-07 | Roth Capital | Initiate | Buy |
| 2022-09-28 | Maxim Group | Initiate | Buy |
| 2021-12-01 | Roth Capital | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 26, 2026
PeriodQ4 / 2025
EPS Estimate-$0.38
Revenue Estimate153K
Revenue Q2Q253.35%
EPS Q2Q-88.70%
Number of Analysts4
Next Earnings Revisions
Revenue (1 Month)
-50.00%
Revenue (3 Months)
-71.15%
EPS (1 Month)
1.33%
EPS (3 Months)
-8.82%
Next Earnings Summary
BRTX is expected to report earnings on 3/26/2026. The consensus EPS estimate for the next earnings is -0.38 USD and the consensus revenue estimate is 153.00K USD.
The next earnings revenue estimate has been revised downward by 71.15% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 120K 140.00% | 145.8K 21.50% | 401K 175.03% | 499.8K 24.64% | 1.938M 287.76% | 48.882M 2,422.29% | 86.014M 75.96% | 246.71M 186.83% | 348.06M 41.08% | 516.4M 48.37% | 804M 55.69% | 887.85M 10.43% | |
| EBITDA YoY % growth | -18.85M 28.11% | -15.055M 20.13% | -11.366M 24.50% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -18.97M 27.90% | -15.221M 19.76% | -11.555M 24.08% | -15.859M -37.25% | -13.527M 14.70% | -15.252M -12.75% | 57.071M 474.19% | 164.07M 187.48% | 239.04M 45.69% | 346.4M 44.91% | 450.77M 30.13% | 497.86M 10.45% | |
| Operating Margin | -15,808.33% | -10,439.51% | -2,881.60% | -3,173.06% | -698.00% | -31.20% | 66.35% | 66.50% | 68.68% | 67.08% | 56.07% | 56.07% | |
| EPS YoY % growth | N/A 1.71% | -3.52 36.62% | -1.16 66.93% | -1.66 -42.84% | -1.16 30.06% | 0.81 169.74% | 5.12 531.45% | 7.50 46.41% | 8.68 15.78% | 9.11 4.94% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.38 -88.70% | -0.30 52.98% | -0.27 11.60% | -0.21 35.09% | -0.22 40.54% |
| Revenue Q2Q % growth | 153K 253.35% | 420.75K 1,583.00% | 612K 101.98% | 663K 5,425.00% | 688.5K 350.00% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.801M -41.28% | -4.288M 10.80% | -4.476M -35.41% | -4.849M -30.74% | -5.035M -32.47% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
39.19%
EPS Next 5 Year
53.21%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
286.04%
Revenue Next 5 Year
210.88%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
BIORESTORATIVE THERAPIES INC / BRTX Forecast FAQ
What do analysts expect the price target to be for BIORESTORATIVE THERAPIES INC (BRTX)?
8 analysts have analysed BRTX and the average price target is 9.69 USD. This implies a price increase of 4451.43% is expected in the next year compared to the current price of 0.2129.
When does BIORESTORATIVE THERAPIES INC (BRTX) report earnings?
BIORESTORATIVE THERAPIES INC (BRTX) will report earnings on 2026-03-26, before the market open.
What are the consensus estimates for BRTX stock next earnings?
The consensus EPS estimate for the next earnings of BIORESTORATIVE THERAPIES INC (BRTX) is -0.38 USD and the consensus revenue estimate is 153.00K USD.
How many analysts have analysed BIORESTORATIVE THERAPIES INC (BRTX)?
The number of analysts covering BIORESTORATIVE THERAPIES INC (BRTX) is 8.